NEWS. When Sciety was founded in 2014, the vision was clear – to bridge the gap between scientific breakthroughs and societal benefit. Ten years later, we have grown to become one of the Nordic region’s leading investors in life science and digital health, with over one billion SEK invested in
INSIGHT. In the pharmaceutical industry, contract development and manufacturing organizations (CDMOs) have taken on an increasingly central role. Over the past decade, these companies have shifted from being mere manufacturing partners to becoming drivers of innovation and technological development. To meet the changing demands of the pharmaceutical industry and the
INSIGHT. We find ourselves in a time when groundbreaking technologies such as artificial intelligence, next-generation DNA sequencing, and data-driven precision medicine rapidly reshape the healthcare landscape. The market for AI in healthcare is projected to exceed 100 billion dollars by 2028, with an annual growth rate of over 47% compared
INSIGHT. Peptides (short chains of amino acids) have long been used in the development of pharmaceuticals, such as diabetes medicine. In recent years, we’ve seen a dramatic increase in peptide-based pharmaceuticals. In 2022, peptide pharmaceuticals accounted for 5 percent of the global pharmaceutical market, with a market value of USD
INSIGHT. Medical advancements that save or improve the lives of others often start in the lab, initiated and driven by the curiosity and determination of individual researchers or research teams. In Sweden, renowned for its exceptional universities, researchers have extensive opportunities to transition their discoveries from the lab to the market,
INSIGHT. Sweden is renowned for its strong position in life science – a tradition of research and development coupled with a favourable ecosystem that fosters collaboration and innovation to drive progress. With Sciety, you can invest in leading Swedish life science companies that aim to be acquired or listed on